Martin Ian Cooper

USPTO Granted Patents = 10 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 34(Granted Patents)

Location History:

Cambridge, GB (2014 - 2019)
Foxton, GB (2014 - 2019)

Company Filing History:

Millennium Pharmaceuticals Limited

patents

1 out of 8

Tobira Therapeutics, Inc.

patents

Years Active: 2014-2019

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10517852 - Solid forms of bendamustine hydrochloride (2019-12-31),

2. 10301287 - Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate (2019-05-28),

3. 10039750 - Solid forms of bendamustine hydrochloride (2018-08-07),

4. 10017513 - Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate (2018-07-10),

5. 10016427 - Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate (2018-07-10),

6. 9533955 - Solid forms of bendamustine hydrochloride (2017-01-03),

7. 9187482 - Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate (2015-11-17),

8. 8883836 - Solid forms of bendamustine hydrochloride (2014-11-11),

9. 8669279 - Solid forms of bendamustine hydrochloride (2014-03-11),

10. 8653064 - Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate (2014-02-18),

Title: Martin Ian Cooper: A Visionary Inventor in Pharmaceutical Innovations

Introduction

Martin Ian Cooper, based in Foxton, GB, is a notable inventor with a remarkable portfolio of ten patents. His contributions to the field of pharmaceuticals have paved the way for significant advancements in drug formulations and therapeutic applications.

Latest Patents

Among his latest inventions, Cooper has developed novel solid forms of bendamustine hydrochloride, detailing methods of their preparation and usage. Additionally, he has focused on solid forms of cenicriviroc mesylate, which includes processes for their development and utilization in pharmaceutical compositions. These patents reflect his dedication to enhancing therapeutic efficacy and safety in drug delivery.

Career Highlights

Throughout his illustrious career, Martin Ian Cooper has made significant contributions while working with prestigious companies such as Cephalon, Inc. and Millennium Pharmaceuticals Limited. His work in these organizations has allowed him to apply his innovative thinking and scientific expertise to real-world medical challenges.

Collaborations

Cooper has collaborated with esteemed colleagues, including Mark D Eddleston and Laurent D Courvoisier. These partnerships have likely enriched his research and invention processes, facilitating the development of groundbreaking pharmaceutical solutions.

Conclusion

Martin Ian Cooper stands out as a prominent figure in the realm of pharmaceutical innovations. With a strong patent portfolio and valuable collaborations, he continues to influence the industry, ensuring that advancements in drug formulation and therapeutic effectiveness are realized for the benefit of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.